Menu
← Oncology Approval Tracker
FDA DECISION ·
Datroway
datopotamab deruxtecan-dlnk · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with locally advanced or metastatic EGFR-mutated NSCLC previously treated with EGFR-directed therapy and platinum-based chemotherapy.
LAMPGEN ANALYSIS
Why it matters
Accelerated approval extended this TROP2 antibody–drug conjugate to a heavily pretreated EGFR-mutated lung cancer population.
What research teams should watch
Verify prior EGFR-targeted therapy and platinum exposure, and specify who triages new pulmonary symptoms.
PRIMARY RECORDS